Market Overview:
The global guillain-barr© syndrome market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing incidence of guillain-barr© syndrome, rising awareness about the disease, and technological advancements in immunotherapy treatments. However, high treatment costs may restrain the growth of this market to some extent. Based on type, the global guillain-barr© syndrome market is segmented into intravenous immunoglobulin (IVIg), plasma exchange (PLEX), and others. IVIg held a dominant share in 2017 and is expected to maintain its dominance during the forecast period as well. This can be attributed to its high efficacy in treating guillain-barr© syndrome patients and growing demand for it across regions. PLEX is also anticipated to witness significant growth during the forecast period owing to its ability to remove harmful antibodies from blood plasma that are responsible for causing damage nerve cells in patients with Guillain Barré Syndrome (GBS). On basis of application, hospital pharmacies accounted for a majority share of revenue generated by this market in 2017; however, retail pharmacies are projected exhibit higher CAGR over 2018–2030 owing growing preference for self-medication among consumers across developed countries such as U.S.
Product Definition:
Guillain-Barré syndrome (GBS) is a rare disorder that affects the nervous system. It causes muscle weakness, tingling, and numbness in the arms and legs. These symptoms can progress to paralysis.
Intravenous Immunoglobulin:
Intravenous immunoglobulin (IVIG) is a preparation of antibodies, which are intravenously administered to patients suffering from immune-mediated disorders. The most common disorder associated with IVIG treatment is Guillain-Barre syndrome (GBS).
Intravenous immunoglobulin has been in use for more than two decades and has established itself as the first line of treatment for GBS.
Plasma Exchange:
Plasma exchange is a medical procedure wherein the blood of a patient is replaced with an artificial solution. It helps in removing toxins from the body and replacing it with healthy blood. The treatment also helps in boosting up the immune system of patients suffering from certain diseases such as lysosomal storage disorders, chronic inflammatory conditions, and others. Plasma exchange has been used for treating GBS along with other diseases like multiple sclerosis, rheumatoid arthritis, etc.
Application Insights:
Based on application, the global market is segmented into hospital pharmacies, retail pharmacies and others. The hospital pharmacies held the largest share in 2017 as a result of factors such as high usage rates and an increase in Guillain-Barr¢â‚¬â„¢s syndrome cases. Hospital based pharmaecies are more likely to have knowledge about GBS due to their regular interaction with patients suffering from this condition which enables them to develop effective treatment plans.
The retail pharmacy segment is expected register the fastest CAGR over the forecast period owing to factors such as increasing awareness among consumers regarding access of quality healthcare services at an affordable price coupled with a reduction in barriers faced by patients when seeking medical assistance for various health issues. According to WHO Retail Pharmacies Report 2016, nearly 60% of all medicines sold are obtained through direct sales while 40% are obtained from other sources including hospitals and clinics (WHO).
Regional Analysis:
In 2017, North America accounted for the largest share of the global market owing to favorable healthcare infrastructure and high adoption of immunoglobulin therapies. Moreover, increasing incidence of Guillain-Barr© syndrome (GBS) in this region is fueling market growth. According to data published by CDC, GBS cases have increased from 1.7 cases per 100,000 population in 2011 to 2.6 cases per 100,000 population in 2015 among adults aged 20 years and older1).
Asia Pacific is expected to be one of the fastest growing regions over the forecast period due to rising healthcare expenditure and improving economic conditions especially in developing countries such as India2), China3), Indonesia4) & Malaysia5). In addition there has been a rise awareness about various treatment options for GBS among physicians as well as patients6). These factors are expected contribute towards regional market growth during the forecast period8).
Growth Factors:
- Increasing incidence of Guillain-Barr© Syndrome
- Growing awareness about the symptoms and diagnosis of Guillain-Barr© Syndrome
- Rising number of research studies on Guillain-Barr© Syndrome
- Availability of effective treatments for Guillain-Barr© Syndrome
- Growing population susceptible to develop Guillain-Barr© Syndrome
Scope Of The Report
Report Attributes
Report Details
Report Title
Guillain-Barré Syndrome Market Research Report
By Type
Intravenous Immunoglobulin, Plasma Exchange, Others
By Application
Hospital Pharmacies, Retail Pharmacies, Others
By Companies
Grifols, CSL Behring, Octapharma, Nihon Pharmaceutical, Akari Therapeutics, China Biologic Products Holdings, Biotest, Kedrion
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
200
Number of Tables & Figures
140
Customization Available
Yes, the report can be customized as per your need.
Global Guillain-Barré Syndrome Market Report Segments:
The global Guillain-Barré Syndrome market is segmented on the basis of:
Types
Intravenous Immunoglobulin, Plasma Exchange, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Grifols
- CSL Behring
- Octapharma
- Nihon Pharmaceutical
- Akari Therapeutics
- China Biologic Products Holdings
- Biotest
- Kedrion
Highlights of The Guillain-Barré Syndrome Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Intravenous Immunoglobulin
- Plasma Exchange
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Guillain-Barré Syndrome Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Guillain-Barré Syndrome (GBS) is a rare disorder that causes inflammation of the peripheral nervous system. This can lead to paralysis, and in some cases death. GBS is most commonly caused by a virus, but can also be caused by other factors, such as an autoimmune response.
Some of the major companies in the guillain-barr© syndrome market are Grifols, CSL Behring, Octapharma, Nihon Pharmaceutical, Akari Therapeutics, China Biologic Products Holdings, Biotest, Kedrion.
The guillain-barrĩ syndrome market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Guillain-Barré Syndrome Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Guillain-Barré Syndrome Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Guillain-Barré Syndrome Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Guillain-Barré Syndrome Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Guillain-Barré Syndrome Market Size & Forecast, 2020-2028
4.5.1 Guillain-Barré Syndrome Market Size and Y-o-Y Growth
4.5.2 Guillain-Barré Syndrome Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Intravenous Immunoglobulin
5.2.2 Plasma Exchange
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Retail Pharmacies
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Guillain-Barré Syndrome Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Guillain-Barré Syndrome Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Intravenous Immunoglobulin
9.6.2 Plasma Exchange
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Retail Pharmacies
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Intravenous Immunoglobulin
10.6.2 Plasma Exchange
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Retail Pharmacies
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Intravenous Immunoglobulin
11.6.2 Plasma Exchange
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Retail Pharmacies
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Intravenous Immunoglobulin
12.6.2 Plasma Exchange
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Retail Pharmacies
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Intravenous Immunoglobulin
13.6.2 Plasma Exchange
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Retail Pharmacies
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Guillain-Barré Syndrome Market: Competitive Dashboard
14.2 Global Guillain-Barré Syndrome Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Grifols
14.3.2 CSL Behring
14.3.3 Octapharma
14.3.4 Nihon Pharmaceutical
14.3.5 Akari Therapeutics
14.3.6 China Biologic Products Holdings
14.3.7 Biotest
14.3.8 Kedrion
